

Malik Peiris, D.Phil.\*  
The University of Hong Kong  
Hong Kong, China

ORCID IDs: 0000-0003-4382-2445 (D.S.H.); 0000-0001-8217-5995 (M.P.).

\*Corresponding author (e-mail: malik@hku.hk).

## References

1. Mok CKP, Chen C, Yiu K, Chan TO, Lai KC, Ling KC, *et al.* A randomized clinical trial using CoronaVac or BNT162b2 vaccine as a third dose in adults vaccinated with two doses of CoronaVac. *Am J Respir Crit Care Med* 2022;205:844–847.
2. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, *et al.* Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology* 2022;27:301–310.

Copyright © 2022 by the American Thoracic Society




## Erratum: Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry

The letter by Min and colleagues (1), published in the March 15, 2021 issue of the *Journal*, relies in part upon data


provided by the Pulmonary Hypertension Association Registry (PHAR). After the article had been published, the PHAR notified investigators who had used their data that an error had occurred when they had calculated the composite scores of the Medical Outcome Study Short Form-12 (SF-12) physical and mental components. The distributed datasets did not accurately reflect scores reported by participants: the coding error failed to reverse code responses for four of the twelve SF-12 questions.

Once the error was discovered by the PHAR team, they notified investigators who had used their data and provided updated corrected datasets. Min and colleagues then extracted the new SF-12 physical and mental scores from the corrected dataset and performed the analysis again. The authors informed the *Journal* that although there were small changes in the effect estimates, the article's conclusions have not changed. However, corrections have been made to the text of the letter, the table, and the figure. Two new panels (1B and 1C) have been added to the figure: panel 1A remains unchanged; the former panel 1B is unchanged but has been relabeled panel 1D.

For the convenience of our readers, the *Journal* is replacing the online version of the article with a corrected version. In addition, a document showing all the changes to



This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).



the data will be posted as an online supplement to the original article. ■

Grinnan D, Ventetuolo C, Al-Naamani N; PHAR Investigators. Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension: the Pulmonary Hypertension Association Registry. *Am J Respir Crit Care Med.* 2021;203:761–764.

**Reference**

1. Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T,

Copyright © 2022 by the American Thoracic Society